<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News .net | Published News | Clinical Trials</title>
<link>http://www.worldpharmanews.net</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Sun, 29 Aug 2010 00:07:28 EEST</pubDate>
<language>en</language>
<item>
<title><![CDATA[GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/</comments>
<pubDate>Sun, 29 Aug 2010 00:07:28 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/</guid>
<description><![CDATA[GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. The phase III clinical trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Study Gives Better Understanding Of How Reoviruses And Chemo Work Together | The Investor Relations Group]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/study-gives-better-understanding-of-how-reoviruses-and-chemo-work-together-%7C-the-investor-relations-group/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/study-gives-better-understanding-of-how-reoviruses-and-chemo-work-together-%7C-the-investor-relations-group/</comments>
<pubDate>Wed, 12 May 2010 21:53:52 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/study-gives-better-understanding-of-how-reoviruses-and-chemo-work-together-%7C-the-investor-relations-group/</guid>
<description><![CDATA[As effective as Gemcitabine is against some cancers, it has not been proven effective as a standalone treatment for eradicating certain other forms such as colon cancer. However, researchers at Weill Cornell Medical Center in New York have demonstrated that a reovirus therapy called REOLYSIN works synergistically with gemcitabine and may be worth further investigation. <br/><br/>16 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Vaccines For HIV And AIDS On The Horizon | The Investor Relations Group]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/vaccines-for-hiv-and-aids-on-the-horizon-%7C-the-investor-relations-group/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/vaccines-for-hiv-and-aids-on-the-horizon-%7C-the-investor-relations-group/</comments>
<pubDate>Wed, 12 May 2010 18:36:37 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/vaccines-for-hiv-and-aids-on-the-horizon-%7C-the-investor-relations-group/</guid>
<description><![CDATA[A company named GeoVax Labs, Inc. may be the first to put vaccines on the market that can help alleviate the suffering that results when HIV progresses to AIDS. Based in Smyrna, GA., the company is at work on both preventative and therapeutic vaccines.<br/><br/>18 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Ranibizumab Injections Plus Laser Therapy Results in Dramatic Visual Improvement]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/ranibizumab-injections-plus-laser-therapy-results-in-dramatic-visual-improvement/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/ranibizumab-injections-plus-laser-therapy-results-in-dramatic-visual-improvement/</comments>
<pubDate>Fri, 30 Apr 2010 14:06:25 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/ranibizumab-injections-plus-laser-therapy-results-in-dramatic-visual-improvement/</guid>
<description><![CDATA[Researchers have shown that ranibizumab eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina. Laser treatment alone has been the standard care for the past 25 years. But nearly 50 percent of patients who received this new treatment experienced substantial visual improvement after one year, comp<br/><br/>6 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New data demonstrating the superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin)]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/new-data-demonstrating-the-superior-efficacy-of-victoza-liraglutide-compared-to-januvia-sitagliptin/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/new-data-demonstrating-the-superior-efficacy-of-victoza-liraglutide-compared-to-januvia-sitagliptin/</comments>
<pubDate>Fri, 23 Apr 2010 15:52:25 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/new-data-demonstrating-the-superior-efficacy-of-victoza-liraglutide-compared-to-januvia-sitagliptin/</guid>
<description><![CDATA[The Lancet published online the results of the first study comparing the once-daily human GLP-1 analogue, Victoza® (liraglutide) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in HbA1c, fasting plasma glucose (FPG) and body weight than Januvia®, with similar or better overall treatment satisfaction.<br/><br/>6 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Once Daily Lixisenatide (AVE 0010) Given as Monotherapy Successfully Meets Phase III Study Endpoints in Diabetes]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/once-daily-lixisenatide-ave-0010-given-as-monotherapy-successfully-meets-phase-iii-study-endpoints-in-diabetes/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/once-daily-lixisenatide-ave-0010-given-as-monotherapy-successfully-meets-phase-iii-study-endpoints-in-diabetes/</comments>
<pubDate>Fri, 16 Apr 2010 14:46:01 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/once-daily-lixisenatide-ave-0010-given-as-monotherapy-successfully-meets-phase-iii-study-endpoints-in-diabetes/</guid>
<description><![CDATA[Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the results of the first, placebo-controlled study of the GetGoal Phase III clinical trial program showed lixisenatide (AVE0010), a once-daily GLP-1 agonist, significantly reduced HbA1c vs. placebo with more patients achieving HbA1c<br/><br/>5 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_starts_phase_1_trial_with_long-acting_oral_GLP-1_analogue/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_starts_phase_1_trial_with_long-acting_oral_GLP-1_analogue/</comments>
<pubDate>Fri, 15 Jan 2010 00:26:36 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_starts_phase_1_trial_with_long-acting_oral_GLP-1_analogue/</guid>
<description><![CDATA[Novo Nordisk has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose <br/><br/>5 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Facet_Biotech_and_Bristol-Myers_Squibb_Report_Promising_Phase_III_Interim_Data_for_Elotuzumab/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Facet_Biotech_and_Bristol-Myers_Squibb_Report_Promising_Phase_III_Interim_Data_for_Elotuzumab/</comments>
<pubDate>Tue, 08 Dec 2009 01:37:15 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Facet_Biotech_and_Bristol-Myers_Squibb_Report_Promising_Phase_III_Interim_Data_for_Elotuzumab/</guid>
<description><![CDATA[Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized ant<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk starts phase 1 trial with oral insulin analogue]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_starts_phase_1_trial_with_oral_insulin_analogue/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_starts_phase_1_trial_with_oral_insulin_analogue/</comments>
<pubDate>Tue, 08 Dec 2009 01:36:09 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_starts_phase_1_trial_with_oral_insulin_analogue/</guid>
<description><![CDATA[Novo Nordisk has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a USD 2 million payment to Merrion Pharmaceuticals plc, whose GIPETÂ® techno<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lundbeck initiates clinical phase II trials with Lu AE58054]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Lundbeck_initiates_clinical_phase_II_trials_with_Lu_AE58054/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Lundbeck_initiates_clinical_phase_II_trials_with_Lu_AE58054/</comments>
<pubDate>Mon, 30 Nov 2009 15:10:14 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Lundbeck_initiates_clinical_phase_II_trials_with_Lu_AE58054/</guid>
<description><![CDATA[H. Lundbeck A/S announced the initiation of a multi-centre, placebo-controlled, fixed-dose study of Lu AE58054 as add-on to donepezil in patients with moderate Alzheimer's disease. The clinical phas<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lower doses of antigen may suffice to generate a protective immune response against A(H1N1)]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Lower_doses_of_antigen_may_suffice_to_generate_a_protective_immune_response_against_AH1N1/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Lower_doses_of_antigen_may_suffice_to_generate_a_protective_immune_response_against_AH1N1/</comments>
<pubDate>Wed, 18 Nov 2009 02:42:24 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Lower_doses_of_antigen_may_suffice_to_generate_a_protective_immune_response_against_AH1N1/</guid>
<description><![CDATA[Novartis announced new interim data from ongoing clinical trials demonstrating that a single 7.5Âµg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved U<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Abbott_Announces_Positive_Three-Year_Data_on_Its_Fully_Bioabsorbable_Stent_Technology/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Abbott_Announces_Positive_Three-Year_Data_on_Its_Fully_Bioabsorbable_Stent_Technology/</comments>
<pubDate>Wed, 18 Nov 2009 02:41:10 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Abbott_Announces_Positive_Three-Year_Data_on_Its_Fully_Bioabsorbable_Stent_Technology/</guid>
<description><![CDATA[Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent s<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Oncolytics_BiotechR_Inc-_Collaborators_Present_Positive_Phase_III_Trial/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Oncolytics_BiotechR_Inc-_Collaborators_Present_Positive_Phase_III_Trial/</comments>
<pubDate>Tue, 17 Nov 2009 18:14:25 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Oncolytics_BiotechR_Inc-_Collaborators_Present_Positive_Phase_III_Trial/</guid>
<description><![CDATA[The investigators reported that REOLYSIN was well tolerated when administered intravenously in combination with paclitaxel and carboplatin. Of 19 evaluable patients with head and neck cancer, mostly <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Amgen_Announces_Overall_Survival_Results_for_VectibixR_in_First-Line_Metastatic_Colorectal_Cancer/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Amgen_Announces_Overall_Survival_Results_for_VectibixR_in_First-Line_Metastatic_Colorectal_Cancer/</comments>
<pubDate>Fri, 06 Nov 2009 12:29:43 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Amgen_Announces_Overall_Survival_Results_for_VectibixR_in_First-Line_Metastatic_Colorectal_Cancer/</guid>
<description><![CDATA[Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating VectibixÂ® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-lin<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[World's largest malaria vaccine trial now underway in seven African countries]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Worlds_largest_malaria_vaccine_trial_now_underway_in_seven_African_countries/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Worlds_largest_malaria_vaccine_trial_now_underway_in_seven_African_countries/</comments>
<pubDate>Fri, 06 Nov 2009 12:28:45 EET</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Worlds_largest_malaria_vaccine_trial_now_underway_in_seven_African_countries/</guid>
<description><![CDATA[A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique a<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Results from second clinical trial of GSK's H1N1 adjuvanted vaccine confirm immune response and tolerability]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Results_from_second_clinical_trial_of_GSKs_H1N1_adjuvanted_vaccine_confirm_immune_response_and_tolerability/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Results_from_second_clinical_trial_of_GSKs_H1N1_adjuvanted_vaccine_confirm_immune_response_and_tolerability/</comments>
<pubDate>Sat, 24 Oct 2009 17:26:45 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Results_from_second_clinical_trial_of_GSKs_H1N1_adjuvanted_vaccine_confirm_immune_response_and_tolerability/</guid>
<description><![CDATA[GlaxoSmithKline (GSK) announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine, which demonstrate that one dose of the vaccine can provide a strong immune response whi<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Novartis_oral_MS_therapy_FTY720_significantly_reduces_relapses_and_disability_progression/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Novartis_oral_MS_therapy_FTY720_significantly_reduces_relapses_and_disability_progression/</comments>
<pubDate>Sat, 03 Oct 2009 17:36:53 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Novartis_oral_MS_therapy_FTY720_significantly_reduces_relapses_and_disability_progression/</guid>
<description><![CDATA[Initial results from the two-year Phase III FREEDOMS study show that oral FTY720 (fingolimod) was significantly superior to placebo in reducing both relapses and disability progression in patients wi<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Results from Abbott's PROSPECT Study Provide New Insight]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Results_from_Abbotts_PROSPECT_Study_Provide_New_Insight/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Results_from_Abbotts_PROSPECT_Study_Provide_New_Insight/</comments>
<pubDate>Fri, 25 Sep 2009 02:08:48 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Results_from_Abbotts_PROSPECT_Study_Provide_New_Insight/</guid>
<description><![CDATA[Abbott (NYSE: ABT) announced primary results from its ground breaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the fir<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Herceptin provides impressive survival benefit for patients with high levels of HER2]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Herceptin_provides_impressive_survival_benefit_for_patients_with_high_levels_of_HER2/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Herceptin_provides_impressive_survival_benefit_for_patients_with_high_levels_of_HER2/</comments>
<pubDate>Fri, 25 Sep 2009 02:07:37 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Herceptin_provides_impressive_survival_benefit_for_patients_with_high_levels_of_HER2/</guid>
<description><![CDATA[A detailed analysis of the Phase III ToGA study revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was adde<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Bayer_Announces_New_Data_on_Oncology_Portfolio_To_Be_Presented_at_the_ECCO-ESMO_Congress_2009/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Bayer_Announces_New_Data_on_Oncology_Portfolio_To_Be_Presented_at_the_ECCO-ESMO_Congress_2009/</comments>
<pubDate>Tue, 22 Sep 2009 02:12:25 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Bayer_Announces_New_Data_on_Oncology_Portfolio_To_Be_Presented_at_the_ECCO-ESMO_Congress_2009/</guid>
<description><![CDATA[Bayer Schering Pharma announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - NexavarÂ® (sorafenib) tablets, regorafenib (BAY 73-4506) an<br/><br/>3 Vote(s) ]]></description>
</item>

</channel>
</rss>
